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Abstract. Although fluoroquinolones are first-line agents 
for the treatment of National Institutes of Health (NIH) 
category II chronic bacterial prostatitis (CBP), therapy with 
these agents is not always feasible due to the increasing world-
wide resistance of causative uropathogens. New therapeutic 
options are urgently required, as drugs such as β‑lactam 
antibiotics distribute poorly to prostatic sites of infection and 
trimethoprim therapy is often unfeasible due to high resis-
tance rates. The present study aimed to analyze the efficacy 
of aminoglycosides, administered to a cohort of 78 patients 
affected by fluoroquinolone‑resistant CBP, or excluded from 
fluoroquinolone therapy due to various contraindications. 
Patients received netilmicin (4.5 mg/kg, once-daily, intramus-
cular), combined or not with a β-lactam antibiotic, for 4 weeks. 
Follow-up visits were scheduled 6 and 12 months after the end 
of treatment. Fifty‑five out of 70 patients (78.6%) showed erad-
ication of the causative pathogen, and a significant reduction 
of the NIH‑Chronic Prostatitis Symptom Index (NIH‑CPSI) 
total score from a baseline median value of 21 to 14 at the end 
of therapy, and to 9 and 8 at 6-month and 12-month follow-up 
assessments, respectively. The pain, voiding and quality of 
life subdomains of the NIH-CPSI decreased accordingly. In 
15 patients showing persistence of infection, NIH-CPSI total 
and subdomain scores did not decrease at the end of therapy. 
Additional clinical parameters, such as the urinary peak 
flow rate, percentage voided bladder, serum prostate‑specific 
antigen concentration, International Prostate Symptom Score 
and prostate volume improved significantly only in the group 
of patients in which the infection was eradicated. Therapy was 
well tolerated, and genetic testing for deafness-predisposing 
mitochondrial mutations allowed safer administration of 
aminoglycosides. These results suggest that aminoglycosides 
may become a therapeutic alternative for the treatment of 
CBP. These findings should be further validated in a random-
ized-controlled setting.
Introduction
There is mounting evidence that a history of clinical chronic 
prostatitis can be a risk factor for prostate cancer (1-7). As 
a consequence, aggressive therapy, aimed at eradicating or 
neutralizing the etiological agents of bacterial or abacterial 
forms of chronic prostatitis, is of great importance for the 
prompt resolution of the severe symptoms of these conditions, 
but may also have implications in cancer prevention.
National Institutes of Health (NIH) category II chronic 
bacterial prostatitis (CBP) and category III chronic prosta-
titis/chronic pelvic pain syndrome are the two main chronic 
symptomatic conditions of the prostate (8). While the latter is 
often treated with a variety of agents in an attempt to target 
its manifold and often uncertain etiological determinants, the 
former is usually managed with antibacterial agents, admin-
istered at high doses and for extended periods of time (weeks, 
or in some cases, months).
Fluoroquinolones such as ciprofloxacin or levofloxacin 
have been first‑line agents for the treatment of CBP for many 
years, due to their broad antibacterial spectrum and efficient 
distribution to the prostate tissue and glandular ducts (9). 
However, f luoroquinolone-based therapy is not always 
feasible, due to specific contraindications (for example, a 
history of tendonitis or long QT syndrome) or to resistance of 
causative uropathogens to these agents (10,11). In this regard, 
the resistance rates of Enterobacteriaceae and other patho-
gens causing community-acquired or healthcare-associated 
urogenital infections are increasing markedly. They exceed 
50% in many parts of the world, particularly in Asia, but 
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similar figures have been reported in other continents. For 
example, fluoroquinolone resistance rates in Europe and 
North America range from ~10% in rural areas to >30% in 
established sexual networks (12).
Although national and international implementation of 
targeted stewardship may eventually decrease the deleterious 
impact of bacterial chemoresistance (13), new therapeutic 
options are urgently required as alternatives to fluoroqui-
nolones. Regretfully, the armamentarium for the outpatient 
treatment of CBP appears to be quite limited, as most β-lactams 
distribute very poorly to the prostatic tissue, and trimethoprim 
therapy is in the majority of cases unfeasible, since world-
wide resistance rates to cotrimoxazole are equivalent to or 
higher than those observed for fluoroquinolones, and cases of 
fluoroquinolone‑cotrimoxazole cross‑resistance are frequently 
reported (14).
Aminoglycosides are among the recommended agents 
for the treatment of category I acute bacterial prostatitis 
(ABP) (15). A retrospective multi-center analysis conducted 
in 2008 showed that an aminoglycoside is administered in 
80% of cases of ABP (16). However, to the best of our knowl-
edge, only case reports or small case series describing the 
successful administration of these agents to patients affected 
by CBP are available (17). Hence, new evidence is required to 
support the usage of aminoglycosides for the treatment of CBP. 
The present study aimed to analyze the efficacy and safety 
of systemic administration of aminoglycoside antibiotics to 
a cohort of 78 patients affected by fluoroquinolone‑resistant 
CBP, or excluded from fluoroquinolone therapy due to various 
contraindications.
Patients and methods 
The Ethics Committee of the Principal Investigator's Hospital 
was notified of the present study, according to Italian bylaws. 
This was a subordinate study of a larger observational inves-
tigation, recorded in the Italian Medicines Agency AIFA 
clinical trial register (no. 276). For an observational retrospec-
tive study, approval is not required, and a simple notification 
accompanying the study protocol is sufficient (Determin-
azione AIFA 20/3/2008, GU 76, 31/3/2008). Patients provided 
written consent for processing and anonymous publication of 
their clinical data. This manuscript was prepared in adher-
ence to the Strengthening the Reporting of Observational 
Studies in Epidemiology Statement (STROBE) guidelines for 
good reporting of observational studies (18). 
Inclusion criteria. The present study was based on the retro-
spective analysis of a database of >1,700 patients with chronic 
prostatitis who were diagnosed and treated on an outpatient 
basis in Milan, Italy. Patients consecutively diagnosed with 
CBP from year 2001 onwards were considered.
Patients between 20 and 65 years of age were included in 
this study in the presence of a clinical indication for treatment 
with aminoglycoside antibiotics of category II CBP, diagnosed 
according to NIH criteria, defined in 1995 at the National 
Institute of Diabetes and Digestive and Kidney Diseases 
Chronic Prostatitis Workshop (Bethesda, MD, USA).
Patients were excluded if they presented any of the following 
conditions: Category I acute bacterial prostatitis, therapy 
with antibacterial agents or any medication effective at the 
prostatic level within a 90-day period prior to aminoglycoside 
treatment, renal/hepatic/cardiac insufficiency, elevated creati-
nine plasma levels, a family history or audiometric evidence 
of hearing impairment, indwelling catheters, cystostomy or 
ureterostomy, previous prostatic surgery or radiotherapy, 
incomplete compliance with antibacterial therapy assessed 
by interviewing patients at test-of-cure visits, any condition 
that might represent a major confounder in the evaluation of 
the patients with the NIH Chronic Prostatitis Symptom Index 
(NIH‑CPSI) for example, chronic consumption of drugs such 
as antidepressants or tramadol. 
Diagnostic procedures and symptom evaluation. CBP was 
diagnosed as previously described in detail (19). Briefly, the 
patient evaluation was based on careful collection of clinical 
history, a urological visit including a digitorectal examination, 
transrectal ultrasound, urine flowmetry [assessment of peak 
urinary flow rate (Qmax)], and on microbiological analysis and 
antibiogram of lower urinary tract specimens obtained with 
the Meares & Stamey ‘4-glass’ test (20). The total ejaculate 
was collected thereafter, and analyzed for pathogens and 
leukocytes, as previously described (21).
For the diagnosis of prostatic bacterial infection, colony 
counts in prostatic specimens (expressed prostatic secretions 
or post‑massage urine) were required to be ≥10‑fold greater 
than those assessed in first‑voided and pre‑massage midstream 
urine. Inflammatory leukocytes were counted in expressed 
prostatic secretions, post-massage urine and semen. In cases 
where infection by more than one pathogen was detected, 
microbiological tests were repeated to exclude accidental 
specimen contamination. Validated Italian versions of the 
NIH-CPSI and International Prostate Symptom Score (IPSS) 
tests were used to score the severity of the clinical symp-
toms (22).
The baseline workup of each candidate to aminoglycoside 
treatment included audiometric testing and measurement of 
serum creatinine.
Study outline. After completing clinical and microbiological 
evaluations at the baseline visit (visit time-point 0, ‘V0’), 
patients were treated with netilmicin (4.5 mg/kg body weight, 
once-daily, intramuscular), combined or not with a β-lactam 
antibiotic. In Italy, treatment of prostatitis is an approved 
indication for aminoglycosides such as netilmicin; hence, 
administration of these agents was on‑label, non‑experi-
mental and part of routine practice. Patients remained from 
time-point V0 to time-point V6 on continuous treatment with 
the α-adrenoceptor blocker alfuzosin (10 mg/day), combined 
with a supplement containing a Serenoa repens extract 
(640 mg/day), lycopene (5 mg/day) and selenium (50 mg/day) in 
a single formulation (Profluss®, Konpharma, Rome, Italy) (23). 
Ketoprofen (160 mg, twice daily) was administered rectally to 
a group (n=11) of mildly febrile patients until normalization of 
the temperature was achieved.
At 4 weeks after the end of the antimicrobial treatment 
all patients were subjected to a complete diagnostic protocol 
including microbiological and clinical evaluations. This 
time-point was designated as visit for assessment of pathogen 
eradication (VERAD).
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At the V6 and V12 follow-up visits (6 and 12 months after 
VERAD, respectively), patients were subjected to complete 
clinical evaluations.
Microbiological response evaluation. The definitions of 
Naber et al were used to report the microbiological response 
to antibacterial therapy: i) Eradication: baseline pathogen was 
eradicated (<103 CFU/ml); ii) eradication with superinfection: 
baseline pathogen was eradicated (<103 CFU/ml) with the 
appearance of a new pathogen (≥103 CFU ml); iii) persis-
tence: baseline pathogen was not eradicated (≥103 CFU/ml); 
iv) persistence with superinfection: baseline pathogen was 
persistent (≥103 CFU/ml) with the appearance of a new pathogen 
(≥103 CFU/ml)(24).
Aminoglycoside ototoxicity risk assessment. There were 
38 patients who gave written consent for genetic analysis 
limited to the 1555A>G, 1494C>T and 1556C>T mutations 
in the mitochondrial DNA, which predispose an individual 
to irreversible sensorineural hearing loss following expo-
sure to aminoglycosides. A specimen of cells was obtained 
from each patient by gently scraping the inner cheek 
mucosa with a sterile mucosal brush. Mitochondrial DNA 
was extracted, using the Quick‑DNA™ Universal kit and 
the DNA Clean & Concentration kit (both Zymo Research 
Corp., Irvine, CA, USA) according to the manufacturer's 
protocol, and used as a template for the identification of 
ototoxicity‑predisposing mutations by two different tech-
niques: Polymerase chain reaction-restriction fragment length 
polymorphism (PCR‑RFLP) (25) and multiplex PCR (26). 
The full sequences of the primers, the final concentration of 
all reagents in the reaction, and the cycling conditions were 
identical to those described by the developers of the two 
analytical techniques (25,26). All personnel analyzing the 
genetic material and the outcome assessor were blinded to the 
identity of the patients. The genetic material was destroyed 
immediately following the release of the anonymized results 
of the mutation analysis. The entire procedure (handling of 
genetic material and data) was legitimated by the General 
Authorization No. 8/2014 for the Processing of Genetic Data, 
of the Italian Data Protection Authority.
Data handling and statistical analysis. To analyze pre- vs. 
post-therapy paired differences in NIH-CPSI and IPSS scores 
the Wilcoxon signed‑rank test was used; intergroup differ-
ences (eradicated vs. persistent cases) were analyzed with 
the Mann‑Whitney‑Wilcoxon rank sum test. The measure of 
central tendency for NIH-CPSI and IPSS ordinal scores was 
the median, and the interquartile range (IQR) was used to 
indicate statistical data dispersion. For continuous variables 
[urinary peak flow rate, serum prostate‑specific antigen (PSA) 
concentration and prostate volume], paired or unpaired t-tests 
were used to analyze differences between means. An α error 
of <5% was set as the significance level for each comparison. 
Comparison between paired patient proportions was made 
using the McNemar's test for correlated proportions.
The VassarStats on-line statistics platform (vassarstats.
net) and the JASP software (jasp-stats.org/) were used for the 
statistical analysis of data. Post-hoc computation of achieved 
power was performed using the G*Power 3.1 program (27).
Results
Clinical presentation of patients and treatment protocols. 
From the clinical database, the data of 93 patients affected 
by category II CBP, for whom therapy with aminoglycoside 
antibiotics was initially considered, were retrieved. The main 
reasons for aminoglycoside indication were resistance of 
causative pathogens to fluoroquinolones, intolerance to fluoro-
quinolones (for example , a history of drug‑induced tendonitis 
or severe gastrointestinal disturbances) or ineffectiveness of 
previous cycles of therapy with fluoroquinolones (Table I).
Fifteen patients refused treatment or were excluded from 
therapy following preliminary otolaryngological tests, kidney 
function evaluations, or careful scrutiny of personal and 
family history (Table II), and 78 cases (median age, 43 years; 
IQR, 22 years) initiated treatment with aminoglycosides, 
combined or not with other antibiotics (β-lactams).
Five different antibacterial protocols were adopted. 
Table III summarizes these protocols, together with the 
rationale for use of the listed agents. All protocols contained 
the aminoglycoside netilmicin (4.5 mg/kg, intramuscular), 
administered once-daily.
Eight patients were noncompliant with therapy or 
dropped‑out during treatment and were excluded from the 
present per‑protocol efficacy analysis.
There were 11 patients who presented with low-grade 
pyrexia (<38.3˚C/101˚F), but did not show the array of signs 
and symptoms typical of acute bacterial prostatitis. In all 
cases, fever resolved within 72‑96 h after the first dose of 
antibiotic. As prostate massage is contraindicated in febrile 
patients until normalization of the temperature occurs, the 
initial diagnosis of prostatitis was based on sonography, 
clinical signs and symptoms and a midstream urine culture, 
eventually followed by the ‘4-glass’ test.
Safety of aminoglycoside therapy. Therapy was in general 
well tolerated. Adverse effects possibly linked to aminogly-
coside exposure were reported in two cases. In 1 patient the 
serum creatinine level increased from 1.1 mg/dl at time-point 
V0 to 2.3 mg/dl at time-point VERAD. This effect was revers-
ible, and the serum creatinine level dropped to 1.2 mg/dl 
8 weeks later. One patient complained of tinnitus by the end 
of treatment, and audiometry confirmed hearing impairment, 
with a notch at 8 KHz. The examining otolaryngologist 
suggested that therapy might have induced the worsening of a 
pre‑existing high‑frequency hearing impairment.
Microbiological results. Eradication of the causative 
pathogen at time-point VERAD was observed in 55 out of 
70 per‑protocol patients (78.6%) and 15 patients exhibited 
microbiological persistence. No cases of superinfection were 
reported.
There were 45 and 22 patients that presented with a 
single-pathogen infection caused by a gram-negative or 
gram-positive pathogen, respectively, whereas 3 patients had 
mixed gram‑positive/gram-negative infections (Table IV). 
Escherichia coli and Enterococcus faecalis were the most 
prevalent pathogens (35 and 19 isolates, respectively). 
Single-pathogen E.faecalis and E.coli infections were eradi-
cated in 56 and 85% of cases, respectively (Table IV). Cases 
MAGRI et al:  AMINOGLYCOSIDE THERAPY FOR CHRONIC BACTERIAL PROSTATITIS2588
of infection recurrence were not reported in the cohort of 
70 treated patients.
Microbiological eradication at time-point VERAD was 
observed in 10 out of 11 febrile patients (90.91%), suggesting 
that aminoglycoside therapy might be an effective therapeutic 
option in certain complicated cases. Such therapy can usually 
be managed in an outpatient setting.
Clinical and laboratory findings. The clinical findings of the 
total patient population at enrollment (V0), at test of eradica-
tion (VERAD) and 6 or 12 months thereafter (time-points V6 
and V12, respectively) are summarized in Fig. 1 and Table V.
Whereas the symptoms of prostatitis did not improve in 
the group of patients exhibiting pathogen persistence, the 
median total NIH-CPSI score, as well as the pain, voiding 
symptom and quality of life (QoL) subdomain scores of 
the NIH‑CPSI decreased significantly in patients showing 
microbiological eradication at time-point VERAD, and 
showed further significant attenuation during follow‑up. A 
caveat is that the statistical power and robustness of unpaired 
comparisons between groups showing microbiological eradi-
cation versus persistence are questionable, as cohorts show 
considerably different sizes (n=55 vs. n=15, respectively), 
and baseline imbalances are present (for example, baseline 
prostate volume).
NIH‑CPSI total score. In patients showing pathogen eradica-
tion, the NIH‑CPSI total score decreased significantly from a 
baseline median value of 21 to 14 at time-point VERAD, and to 
9 and 8 at time-points V6 and V12, respectively (P<0.001 for all 
paired comparisons vs. V0, Wilcoxon signed rank test, n=55). 
The differences between VERAD and V6/V12, and between 
V12 and V6 are also significant (P<0.001; Wilcoxon, n=55).
In patients showing persistence of infection, the score at 
VERAD was not significantly different from baseline values.
A clinically appreciable reduction (28) of ≥6 points of the 
total score of the NIH-CPSI questionnaire was achieved in 32 
out of 55 (58%) patients in which infection was eradicated, and 
in 4 out of 15 (26%) patients with persistent infection (P<0.05, 
two-tailed probability associated with the z-ratio, n=55).
NIH‑CPSI pain domain. In the patients in which eradication of 
infection was successful, the NIH-CPSI pain score decreased 
significantly at VERAD, declined further at time‑point V6, 
and remained unchanged at V12 (Fig. 1). In patients showing 
persistence of infection, the median pain score at VERAD 
was not significantly different from baseline values.
The disease severity was categorized using the full pain 
domain score of the NIH-CPSI, according to Wagenlehner’s 
criteria (29). At time-point V0, 27 patients in the eradicated 
group showed mild pain (0-7 points), 22 patients moderate 
pain (8-13 points) and 6 severe pain (14-21 points). At the 
end of therapy 49, 6 and 0 patients showed mild, moderate 
and severe pain, respectively [P<0.01, two‑tailed McNemar's 
test for correlated proportions, dichotomized data (mild vs. 
moderate/severe), n=55].
Voiding signs and symptoms. Voiding symptom scores 
decreased significantly at VERAD in the eradicated group, 
and were sustained at time-points V6 and V12 (Fig. 1). This 
finding was also evident when the results of the IPSS test 
were analyzed (Table V). In patients showing persistence of 
infection, the voiding symptom scores at VERAD were not 
significantly different from baseline values.
The reduction of voiding symptoms was confirmed 
by assessment of the peak urinary flow and of the bladder 
voiding efficiency: Mean Qmax increased from 17.93 ml/sec 
at V0 to 18.97 ml/sec at VERAD, and the percentage bladder 
voided volume (%BVV; 89% of total bladder content at V0) 
was also significantly increased at VERAD (98%) (P<0.05 for 
Table I. Rationale for aminoglycoside therapy.
 Adverse effects to first‑line agents
 -------------------------------------------------------------------------- Resistance of 
Persistence after   causative pathogens 
first‑line agents Gastrointestinal  Tendonitis to first‑line agents Patients, n
Yes      3
 Yes   11
  Yes    7
   Yes 15
Yes  Yes    2
 Yes  Yes   5
  Yes Yes   6
Yes Yes Yes    6
 Yes Yes  14
 Yes Yes Yes   9
Rationale for aminoglycoside therapy in the patient population (n=70) was based on the following single or combined factors: Persistent 
infection after full‑dose first‑line oral therapy (750 mg/day levofloxacin or 1 g/day ciprofloxacin for 4‑6 weeks) directed against fluoroqui-
nolone‑susceptible pathogens; a history of moderate or severe adverse effects to fluoroquinolones; and resistance of causative pathogens to 
fluoroquinolones.
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both comparisons, paired, two-tailed t-test, n=55; Table V); 
these two signs remained sustainedly improved throughout 
the entire follow-up period.
In patients showing pathogen persistence, a significant 
increase of the peak urinary flow (from 18.2 ml/sec at V0 
to 19.9 ml/sec at VERAD) was observed. In this cohort, as 
well as in the larger cohort of patients in which infection was 
eradicated, the administration of alfuzosin up to time-point 
V6 may have acted as a major confounder, and no conclusion 
can be drawn from data concerning short-term improve-
ment of voiding symptoms. However, Fig. 1 shows that the 
improvement of voiding symptoms was sustained at the 
1-year follow-up time-point (V12), when patients had been off 
alfuzosin therapy for 6 months.
NIH‑CPSI QoL domain. Pain and voiding symptom relief, 
assessed with the NIH‑CPSI test, resulted in significant and 
sustained attenuation of the impact of the disease on QoL 
Table II. Rationale for rejection or contraindication of treatment following initial general indication of aminoglycoside therapy.
Rationale Patients, n
Professional musician   1
Semiprofessional involvment in music or professional activity requiring fine hearing   5
Referred history of reversible hearing impairment upon treatment with aminoglycosides   2
High frequency (4,000 Hz) hearing impairment assessed during audiometry performed 
prior to aminoglycoside therapy initiation    2
Bilateral hearing impairment in family with matrilinear hearing loss   2
Elevated serum creatinine assessed during previous exposure to amikacin    1
Unilateral hearing impairment referred during anamnestic interview prior to aminoglycoside 
therapy initiation    2
Referred tinnitus plus recurrent otitis   1
Total 15
Table III. Antibacterial protocols administered to CBP patients and rationale for drug selection.
Therapeutic
protocol Drugs and dosages Rationale
1 Netilmicin, intramuscular, Cefuroxime was administered to exploit the synergic activity
 4.5 mg/kg, once daily for 2 weeks. of combined aminoglycosides and β-lactams; this 2nd
 Cefuroxime axetil, oral, 250 mg, generation cephalosporin showssufficient prostate penetration (43).
 twice daily for 2 weeks Pathogen sensitivity was assessed by antibiogram
2 Netilmicin, intramuscular, Cefoperazone was administered to exploit the synergic activity
 4.5 mg/kg, once daily for 2 weeks. of combined aminoglycosides and β-lactams; this 3rd generation
 Cefoperazone, intramuscular, 1 g,  cephalosporin shows sufficient prostate penetration (43). 
 twice daily for 2 weeks Pathogen sensitivity was assessed by antibiogram
3 Netilmicin, intramuscular,   Piperacillin was administered to exploit the synergic activity of
 4.5 mg/kg, once daily for 2 weeks. combined aminoglycosides and β-lactams in the presence of
 Piperacillin, 2 g, plus tazobactam,  resistance to cephalosporins (pathogen sensitivity assessed by
 250 mg, intramuscular,  antibiogram), or upon cephalosporin contra-indication. Piperacillin
 once daily for 2 weeks shows adequate prostate penetration (44)
4 Netilmicin, intramuscular,   Co‑amoxiclav can be recovered in the prostate tissue (44),
 4.5 mg/kg, once daily for 2 weeks. and was administered to exploit the synergic activity of combined
 Co‑amoxiclav 875 mg + 125 mg, aminoglycosides and β-lactams in the presence of resistance
 oral, twice daily for 2 weeks to cephalosporins (pathogen sensitivity assessed by antibiogram),
  or of contraindication to cephalosporins or piperacillin
5 Netilmicin, intramuscular, 4.5 mg/kg, Netilmicin was administered as single agent when causative 
 once daily for 2 weeks pathogens showed resistance to β-lactams.
CBP, chronic bacterial prostatitis.
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in patients with eradiation of infection, but not in patients 
showing persistent infection (Fig. 1).
Sonography and laboratory assessments. A significant reduc-
tion of the prostatic volume was identified in patients showing 
Table V. Serum PSA, prostate volume, Qmax, % voided bladder and IPSS at various time points.
 Study time point
 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Variable V0 VERAD V6 V12
PSA (ng/ml)     
  Eradicated 3.32±2.89 1.89±1.37a NA NA
  Persistent  3.31±3.73 2.29±1.98b,c NA NA
Prostate volume (ml)     
  Eradicated 30.0±15.44 24.6±12.17a NA NA
  Persistent  25.5±9.21 25.27±14.50c,d NA NA
Qmax (ml/sec)     
  Eradicated 17.93±7.25 18.97±5.62b 19.32±5.48b 18.66±4.06b
  Persistent  18.21±5.60 19.93±5.73b,c NA NA
% voided bladder     
  Eradicated 88.95±17.25 97.75±9.18b 97.90±8.00b 96.75±12.04b
  Persistent  93.85±11.37 97.66±9.03c,d NA NA
IPSS score    
  Eradicated      12 (9) 8.5 (5.5)e 7 (4.25)e 7 (5)e
  Persistent 10.25 (3)   9 (3)f,g NA NA
Results were measured at baseline (V0), at test of microbiological eradication (VERAD), and at 6 or 12 months follow-up (V6 and V12, 
respectively). Results are stratified according to the microbiological outcome of therapy (eradicated vs persistent infection). Median values and 
interquartile ranges (in parentheses) of the IPSS, and mean ± standard deviations of all other endpoints are presented. Due to the retrospective 
nature of the study, some follow-up data are missing, as patients showing microbiological persistence were managed with a different, third-level 
diagnostic and therapeutic protocol. aP<0.0001 vs. V0, paired t-test; bP<0.05 vs. V0, paired t-test; cP≥0.05, intergroup comparison (unpaired 
t-test); dP≥0.05 vs. V0, paired t‑test; eP<0.05 vs. V0, paired comparison (Wilcoxon signed rank test) ; fP≥0.05 vs. V0, paired comparison 
(Wilcoxon signed rank test); gP≥0.05, intergroup comparison (Mann‑Whitney‑Wilcoxon rank sum test). VERAD, visit for assessment of pathogen 
eradication; IPSS, International Prostate Symptom Score; Qmax, urinary peak flow rate; PSA, serum prostate‑specific antigen; NA, not assessed.
Table IV. Microbiological eradication of each pathogen, assessed at time-point VERAD in the per-protocol study cohort of a total 
of 70 patients.
Pathogen Eradicated, n (%) Persistent, n (%) Total cases
Escherichia coli 29 (85.29) 5 (14.71) 34
Enterococcus faecalis  9 (56.25) 7 (43.75) 16
Staphylococcus aureus 2 (100.00) - 2
Proteus mirabilis 2 (100.00) - 2
Klebsiella oxytoca 2 (66.67) 1 (33.33) 3
Pseudomonas aeruginosa 1 (100.00) - 1
Enterobacter cloacae - 1 (100.00) 1
Morganella morganii 1 (50.00) 1 (50.00) 2
Haemophylus spp. 1 (100.00) - 1
Citrobacter spp.  1 (100.00) - 1
Streptococcus β‑haemolyticus 4 (100.00) - 4
E. faecalis plus E. coli 1 (100.00) - 1
E. faecalis plus P. aeruginosa 2 (100.00) - 2
Total 55 (78.57) 15 (21.43) 70
VERAD, visit for assessment of pathogen eradication.
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pathogen eradication at time-point VERAD (mean differ-
ence, 5.4 ml lower; P<0.0001, paired t-test, n=55), but not in 
patients not responding to the antibacterial therapy (25.27 ml 
at VERAD vs. 25.5 ml at V0; P≥0.05, n=15).
The mean PSA serum level decreased significantly in 
the eradicated group (mean difference, 0.23 ng/ml lower; 
P<0.0001, n=55). However, PSA also decreased significantly 
in patients showing pathogen persistence (2.29 at VERAD vs. 
3.31 at V0; P<0.05, n=15).
Study power. Post-hoc computation of achieved power of the 
analyses was based on an α error probability of 0.05, a calcu-
lated correlation between paired datasets equal to 0.7 and a 
sample size of 55 patients with eradicated infection. The esti-
mated power for the pre- and post-therapy paired comparison 
of the total score of the NIH‑CPSI test was >0.9. Sensitivity 
analysis, given a sample size of 55, a normal distribution 
(two-tailed), an α error probability of 0.05, and an imputed 
power of 0.99, resulted in a required effect size of 1.007 (the 
effect size for the above comparison calculated in the present 
study was 1.2). 
Discussion 
Few drugs are able to reach the prostatic ducts or acini via the 
systemic circulation, due to the existence of a blood‑prostate 
barrier activity preventing the distribution of a number of 
chemicals, including antibacterial agents, to the various cells 
and regions within the gland (30). 
Goto et al authored one of the few studies investigating 
the distribution of aminoglycosides and other four different 
antibacterials to prostatic f luid/secretions (31). It was 
shown that the aminoglycoside amikacin (200 mg, intra-
muscular) reached the highest concentrations in prostatic 
fluids (3.2 µg/ml), compared with β-lactams (piperacillin, 
0.3 µg/ml), tetracyclines (minocycline, 0.62 µg/ml) or fluoro-
quinolones (ofloxacin, 1.3 µg/ml), although the latter showed 
the highest prostatic fluid‑to‑serum ratio (ofloxacin: 0.9; 
amikacin: 0.25) (31). Notably, patients enrolled in the study 
by Goto et al were not affected by acute prostatitis, known 
to facilitate the distribution of any drug to the prostate (31). 
Thus, positive evidence is available about the distribution of 
certain aminoglycosides to the sites of chronic infection in 
the prostate.
Cure of CBP achieved with aminoglycosides was reported 
as early as 1976 and 1991 by Pfau and Sacks in isolated cases 
or a small series of patients treated with parenteral kanamycin 
(1 g twice daily for 3 days, and 500 mg twice daily for 11 days; 
n=13) or streptomicin (1 g/day for 12 days; 1 case) (32,33), 
but to the best of our knowledge the overall evidence in this 
respect is scant.
Within the limits of an observational study, the data in 
the present study show that microbiological eradication and 
sustained clinical symptom remission was achieved in 79% 
of patients (or 71%, if a intent‑to‑treat setting is considered, 
including 8 noncompliant/dropped-out patients) subjected to 
a course of treatment with an aminoglycoside, administered 
alone or in combination with a β-lactam antibiotic. Notably, 
Figure 1. NIH-CPSI scores, assessed at baseline (time-point V0), at test of microbiological eradication (VERAD), and at follow-up (V6 or V12, 6 or 12 months 
after VERAD, respectively). Results are stratified according to the microbiological outcome of therapy (eradication vs. persistence of infection). Median values 
of NIH-CPSI scores are indicated, and interquartile range bars are shown. (A) Pain domain, (B) voiding symptoms domain, (C) impact of the disease on 
patients’ QoL and (D) total NIH-CPSI scores. Due to the retrospective nature of the study, the follow-up data of patients showing microbiological persistence are 
missing, as these patients were routed towards a third-level diagnostic and therapeutic protocol. *P<0.001 vs. V0, paired comparison (Wilcoxon signed rank test). 
**P<0.001 vs. VERAD, paired comparison (Wilcoxon signed rank test). ***P<0.05 vs. V6, paired comparison (Wilcoxon signed rank test). #P≥0.05 vs. V0, paired 
comparison (Wilcoxon signed rank test). §P<0.01, intergroup comparison at VERAD (eradication vs. infection persistence groups), Mann‑Whitney‑Wilcoxon 
rank sum test. §§P≥0.05, intergroup comparison at VERAD (eradication vs. infection persistence groups), Mann‑Whitney‑Wilcoxon rank sum test. NIH‑CPSI, 
National Institutes of Health Chronic Prostatitis Symptom Index; VERAD, visit for assessment of pathogen eradication; QoL, quality of life.
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similar pathogen eradication rates, ranging between 70 and 
80%, have been reported in the past in CBP patients treated 
with various fluoroquinolones (19,24,34,35). In summary, 
the results of the present study suggest that aminoglycosides 
may be administered to selected CBP patients, provided that 
candidates to therapy are at low risk for the serious adverse 
effects of these agents.
Therapy with aminoglycosides exposes patients to the 
risk of hearing impairment. In particular, the carriers of 
the 1555 A>G point‑mutation within the mitochondrial 
DNA locus of the 12S ribosomal RNA develop profound 
and irreversible non-syndromic sensorineural hearing loss 
even after short‑term exposure to aminoglycosides (36). 
One in 520 (0.19%) European children, 6 in 865 Chinese 
newborns (0.7%), and 1 in 500 adults of European descent 
(0.2%) are estimated to be carriers of this mutation, and are 
at risk for such severe toxic effects (37‑39). Other important 
ototoxicity‑predisposing mutations have been discovered, for 
example the 1494 C>T and 1556 C>T substitutions in the same 
12S rRNA (40,41). In our routine clinical practice, consenting 
patient candidates for aminoglycoside therapy are screened for 
a small panel of mutations predisposing to severe, irreversible 
hearing loss. This preliminary analysis can be performed in 
few hours prior to the first dose of the antibiotic, and allows 
safer administration of aminoglycosides. However, a negative 
pharmacogenetic examination result does not exempt patients 
from less severe forms of hearing impairment, possibly caused 
by reactive oxygen species. Administration of aspirin has been 
shown to partly protect patients from these forms of ototox-
icity (42).
In conclusion, administration of aminoglycosides eradi-
cated causative pathogens in 79% of patients and significantly 
decreased the symptoms of the disease, as assessed with the 
NIH-CPSI and IPSS questionnaires. The impact of CBP 
on the QoL of patients was also significantly attenuated. 
Therapy was also effective in significantly decreasing the 
prostate volume, probably by acting on inflammatory edema. 
The therapy was in general well tolerated, and genetic testing 
for mitochondrial mutations predisposing to sensorineural 
deafness allowed safer administration of the antibiotic in a 
considerable fraction of patients. Thus, the data presented 
in this paper indicate that aminoglycosides may be an inter-
esting option for the treatment of CBP in specific, carefully 
selected cases. These findings should be confirmed and 
further validated in a randomized-controlled setting.
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